Prostate Cancer Therapeutics Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, and Others), End Us

Prostate Cancer Therapeutics Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Hormonal Therapy, Chemotherapy, Targeted Therapy, Immunotherapy, and Others), End User (Hospitals, Specialty Clinics, and Others), and Geography

The prostate cancer therapeutics market is expected to grow from US$ 14.767 billion in 2022 to US$ 28.425 billion by 2030; it is anticipated to record a CAGR of 8.5% from 2022 to 2030.

Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years. Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that often develops without noticeable symptoms, and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra, or in some cases, bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer. Prostate cancer is the 5th leading cause of cancer death among men worldwide and the 2nd most commonly diagnosed cancer.

Strong Product Pipeline Creates Opportunity for the Growth of the Prostate Cancer Therapeutics Market

The current landscape for prostate cancer therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Multiple prostate cancer therapies are in various stages of clinical development; pharmaceutical giants are working to expand their pipeline, which is a major opportunity prevailing in the prostate cancer therapy market. A few of the prostate cancer therapies that are in different phases of clinical studies are mentioned below:

Sr. No.

Manufacturer

Product Name

Clinical Trial Phase

1

AstraZeneca
capivasertib
Clinical Phase II
capivasertib + abiraterone CAPItello-281 Clinical Phase III

2

Pfizer PF-07220060 + enzalutamide
Clinical Phase I
PF-06821497 + enzalutamide Clinical Phase II

3

Lilly
Abemaciclib
Clinical Phase III

Source: ClinicalTrials.gov
A strong product pipeline for the treatment of prostate cancer using chemotherapy, targeted therapy, and combinational therapy is expected to fuel the growth of the prostate cancer therapeutics market shortly.

The prostate cancer therapeutics market is divided based on therapy type, end user, and geography. The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. The prostate cancer therapeutics market, by end-user, is segmented into hospitals, specialty clinics, and others.

Based on geography, the prostate cancer therapeutics market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the global prostate cancer therapeutics market in 2022 owing to the increasing technological advancements, increasing number of prostate cancer cases, government support for the growing product pipeline, and major market players engaged in new and existing product developments. However, Asia Pacific is anticipated to register the highest CAGR from 2022 to 2030. The US held the largest share of North America's prostate cancer therapeutics market in 2022. The growth of the prostate cancer therapeutics market in the US is mainly driven by the increasing incidence of prostate cancer cases, product launches, and government initiatives. Various product launches by companies to treat prostate cancer also bolstered market growth. For instance, in June 2023, AstraZeneca and MSD’s Lynparza (olaparib) in combination with prednisone or prednisolone and abiraterone was approved in the US for the treatment of adult patients with suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). In addition, in November 2023, the FDA approved enzalutamide, a product manufactured by Astellas Pharma US, Inc., which is used for the treatment of non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). Other than skin cancer, prostate cancer is one of the most common cancers diagnosed in American men. According to the American Cancer Society Inc., it is estimated that in 2023, ~288,000 new cases of prostate cancer will be registered, and about 34,700 people are expected to die due to prostate cancer. As per the same source, ~ 1 in 8 men will be diagnosed with prostate cancer during their lifetime. This increasing prevalence of prostate cancer in the US and growing awareness about early detection and early treatment of prostate cancer in the US is fueling the growth of the prostate cancer therapeutics market.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and International Organization for Standardization (ISO) are a few key primary and secondary sources referred to while preparing the report on the prostate cancer therapeutics market.

Please Note: It will take 3-5 business days to complete the report upon order confirmation for delivery of the full report and excel data pack.